

If you've been researching medical weight loss, two names come up again and again: semaglutide and tirzepatide. Both are once-weekly injections backed by large clinical trials. Here's a plain-language comparison.
Semaglutide is a GLP-1 receptor agonist. It mimics a natural gut hormone that tells your brain you're full, slows how quickly your stomach empties and helps regulate blood sugar. For many people, that means a smaller appetite and fewer cravings.
Tirzepatide is a dual GIP and GLP-1 receptor agonist. It does everything a GLP-1 does and also activates a second hormone pathway, which is the main reason it has produced larger average weight loss in studies.
Averages aren't guarantees. Results depend on dose, consistency, nutrition, activity and sleep.
Both share similar, mostly digestive side effects such as nausea, constipation or diarrhea, usually strongest when starting or increasing a dose. Neither is appropriate for people with a personal or family history of medullary thyroid carcinoma or MEN2, or for anyone who is pregnant or planning a pregnancy.
GLP-1 medications are generally considered for adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition. Your provider will review your health history and goals before recommending either one. Both are available in the Weight Loss collection, along with B-12 and Lipo-Lean support. Right now, code FALL20 takes 20% off orders of $250 or more through November 30.
New to the Evolv at-home shop? Use code WELCOME15 for 15% off your first order at evolv.axentrahealth.com. Prefer to talk it through in person? Book a consultation at Evolv Wellness MedSpa, 2503 Elmira Street, Aurora, CO, or call 720-661-9024.
This article is for educational purposes and is not medical advice. Prescription products require an online intake and approval by a licensed provider, and are dispensed by an NABP-accredited pharmacy. Availability varies by state. Individual results vary.
Lindsay Wilson, RN, Evolv Wellness MedSpa